We evaluated the effects of Smurf2 knockdown by both genetic ablation (siRNA) and pharmacological inhibition (using the small molecule inhibitor bortezomib, which we also showed downregulates Smurf2) combined with cisplatin chemotherapy and irradiation in two different NSCLC cell lines, PC9 and A549, and observed that Smurf2 knockdown led to significantly reduced cell survival. The gene discussed is SMURF2; the disease is non-small cell lung carcinoma.